Traded Nov 25, 2025 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Traded Oct 24, 2025 · Filed Oct 28, 2025
The CEO of Thermo Fisher Scientific sold $714K of Thermo Fisher Scientific shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$713,554
Shares × reported transaction price
2 days after results of Oct 22, 2025, 97 days before results of Jan 29, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $572.50 on Oct 24, 2025, 47% above its 52-week low and 6% below its high, after a 19% rise over the previous 30 trading days
52-week range $390.26 (Jun 17, 2025) to $606.74 (Jan 30, 2025), 84% of the way up, from 250 adjusted closes. 30 trading days earlier: $479.46 on Sep 12, 2025. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +1.7% | −1.4% | +3.1% |
| 30 days | +5.8% | −0.6% | +6.4% |
| 90 days | +11.8% | +1.2% | +10.6% |
| 180 days | −16.2% | +4.0% | −20.2% |
Past results only. Not a forecast.
Traded Nov 25, 2025 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Michael D Shafer (Executive Vice President) sold ~$5.08M of Thermo Fisher Scientific
Scheduled in advanceTraded Nov 25, 2025 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.